Please login to the form below

Not currently logged in
Email:
Password:

Gilead to acquire Arresto Bioscences

Gilead will acquire Arresto Biosciences for $225m plus potential future payments based on sales levels

Gilead will acquire Arresto Biosciences for $225m plus potential future payments based on sales levels.

Arresto Viosciences is a privately held development-stage technology company focused on medicines to treat fibrotic diseases and cancer. The agreement will provide Gilead with access to Arresto's lead product, AB0024, a monoclonal antibody in phase I trials for the treatment of cancer and idiopathic pulmonary fibrosis. Gilead has a treatment called ambristentan for the same lung disease.

Norbert W Bischofberger, Gilead's executive vice president and chief scientific officer said: "Arresto's research and development expertise is well aligned with Gilead's areas of focus, including our ongoing clinical programme for ambrisentan in IPF. We look forward to working with the team from Arresto to advance the development of novel therapies for serious fibrotic diseases and explore their potential for the treatment of tumours."

Gilead anticipates the deal will close in the first quarter of 2011, subject to satisfaction of certain closing conditions and plans to finance the cash acquisition.

21st December 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics